Loading...
XNASPMD
Market cap15mUSD
Dec 12, Last price  
2.67USD
Name

Psychemedics Corp

Chart & Performance

D1W1MN
XNAS:PMD chart
P/E
P/S
0.71
EPS
Div Yield, %
5.08%
Shrs. gr., 5y
0.77%
Rev. gr., 5y
-12.33%
Revenues
22m
-12.45%
18,937,11121,388,51323,425,09024,568,82422,948,60416,954,99420,108,86224,089,60825,223,53426,870,29729,204,81826,975,40638,980,00039,701,00042,674,00037,678,00021,360,00024,909,00025,240,00022,098,000
Net income
-4m
L+283.21%
2,763,7834,048,5134,902,2014,483,6872,968,7891,527,2952,613,7203,489,2832,979,6293,805,2103,206,0811,511,1766,678,0006,121,0004,584,0001,542,000-3,859,000-665,000-1,084,000-4,154,000
CFO
-1m
L
2,268,8954,350,6884,605,1694,890,7173,687,4932,399,5823,295,3973,935,2013,086,7315,951,5474,457,2334,579,8379,269,0009,146,0007,929,0004,309,000-4,083,000414,0004,890,000-1,480,000
Dividend
May 24, 20230.07 USD/sh
Earnings
Mar 26, 2025

Profile

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
IPO date
Jan 22, 1987
Employees
133
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
22,098
-12.45%
25,240
1.33%
Cost of revenue
25,019
26,323
Unusual Expense (Income)
NOPBT
(2,921)
(1,083)
NOPBT Margin
Operating Taxes
716
44
Tax Rate
NOPAT
(3,637)
(1,127)
Net income
(4,154)
283.21%
(1,084)
63.01%
Dividends
(799)
(1,186)
Dividend yield
4.70%
4.30%
Proceeds from repurchase of equity
(54)
(78)
BB yield
0.32%
0.28%
Debt
Debt current
2,401
1,331
Long-term debt
2,938
5,218
Deferred revenue
(1,188)
Other long-term liabilities
(305)
Net debt
3,375
1,799
Cash flow
Cash from operating activities
(1,480)
4,890
CAPEX
(157)
(187)
Cash from investing activities
(159)
(208)
Cash from financing activities
(1,147)
(1,924)
FCF
(3,531)
5,146
Balance
Cash
1,964
4,750
Long term investments
Excess cash
859
3,488
Stockholders' equity
(18,375)
(13,422)
Invested Capital
28,393
25,503
ROIC
ROCE
EV
Common stock shares outstanding
5,740
5,626
Price
2.96
-39.65%
4.90
-30.13%
Market cap
16,990
-38.43%
27,594
-29.16%
EV
20,365
29,393
EBITDA
(251)
2,233
EV/EBITDA
13.16
Interest
43
Interest/NOPBT